Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. prostate gland
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Prostate Gland Articles & Analysis

15 news found

Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in ...

ByBayer AG


Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.7 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. ...

ByBayer AG


Nubeqa approved for additional indication in Japan

Nubeqa approved for additional indication in Japan

Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the ...

ByBayer AG


New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

“An important part of our mission at Bayer is to transform prostate cancer care and improve patient outcomes at various stages of the disease. ...

ByBayer AG


CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.6 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. ...

ByBayer AG


Treatment of Prostatitis - What Forms of Medicines Released?

Treatment of Prostatitis - What Forms of Medicines Released?

Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...

ByProUroCare Medical Inc.


New ARASENS data reinforce strong tolerability profile of darolutamide plus ADT and docetaxel without compromising quality of life for patients with mHSPC

New ARASENS data reinforce strong tolerability profile of darolutamide plus ADT and docetaxel without compromising quality of life for patients with mHSPC

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.[2] At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. ...

ByBayer AG


U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

” “Prostate cancer is the most common cancer among men in the U.S., with chances of survival decreasing dramatically for those diagnosed with mHSPC compared to localized prostate cancer,” said Charles J. ...

ByBayer AG


First Dexter surgeries in urology carried out in Bern

First Dexter surgeries in urology carried out in Bern

One procedure aimed to remove localized cancers (radical prostatectomy), another treated an enlarged prostate gland (Millin’s prostatectomy). A radical prostatectomy entails the removal of the entire prostate gland and attached seminal vesicles. In a Millin’s procedure only the part of the prostate ...

ByDistalmotion SA


Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference

Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference

During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory Group. The group is comprised of five experienced physicians with extensive experience using Cesium-131 monotherapy for permanent prostate brachytherapy who came together to form the advisory group. Commenting on the presentations, ...

ByTheragenics


U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)

U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for darolutamide in combination with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC)

About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.1 At the time of diagnosis, most men have localized prostate cancer, ...

ByBayer AG


Announcement – New AI Tool for Prostate MRI Analysis to Support PI-RADS Scoring

Announcement – New AI Tool for Prostate MRI Analysis to Support PI-RADS Scoring

Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management. RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced Artificial Intelligence (AI) and computer vision solutions, today announces a new tool for ...

ByRSIP Vision


Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer

Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer

About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.(1) At the time of diagnosis, most men have localized prostate cancer, ...

ByBayer AG


Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.(1) At the time of diagnosis, most men have localized prostate cancer, ...

ByBayer AG


Cancer Targeted Technology Receives $2 Million Small Business Innovation (SBIR) Grant to Advance its PET Imaging Diagnostic to Clinical Trials in Prostate Cancer

Cancer Targeted Technology Receives $2 Million Small Business Innovation (SBIR) Grant to Advance its PET Imaging Diagnostic to Clinical Trials in Prostate Cancer

Cliff Berkman, Professor of Chemistry at Washington State University and CTT Chief Scientific Officer, may be well-suited for imaging the location of cancer metastases that have escaped the prostate gland. Unlike other prostate cancer targeting agents, CTT1057, is a small molecule that homes and binds irreversibly to Prostate ...

ByCancer Targeted Technology

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT